STAAR Surgical Company (STAA)
| Market Cap | 1.24B -12.1% |
| Revenue (ttm) | 339.59M +51.3% |
| Net Income | 3.84M |
| EPS | 0.08 |
| Shares Out | 50.14M |
| PE Ratio | 320.34 |
| Forward PE | 28.57 |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 928,449 |
| Open | 24.07 |
| Previous Close | 24.09 |
| Day's Range | 23.75 - 25.03 |
| 52-Week Range | 15.59 - 35.87 |
| Beta | 1.23 |
| Analysts | Hold |
| Price Target | 27.90 (+13.23%) |
| Earnings Date | Aug 12, 2026 |
About STAA
STAAR Surgical Company, together with its subsidiaries, designs, develops, manufactures, and sells phakic implantable lenses for the eye and accessory delivery systems to deliver the lenses into the eye. The company offers implantable collamer lens product family (ICLs) comprising EVO ICL, EVO+ ICL, EVO Visian ICL, and EVO Viva ICL for use in refractive surgery for the treatment of visual disorders, such as myopia, hyperopia, astigmatism, and presbyopia. It serves health care providers, including ophthalmic surgeons, vision and surgical centers... [Read more]
Financial Performance
In fiscal year 2025, STAAR Surgical Company's revenue was $239.44 million, a decrease of -23.72% compared to the previous year's $313.90 million. Losses were -$80.45 million, 298.1% more than in 2024.
Financial StatementsAnalyst Summary
According to 12 analysts, the average rating for STAA stock is "Hold." The 12-month stock price target is $27.9, which is an increase of 13.23% from the latest price.
News
Staar Surgical price target lowered to $28 from $31 at Stifel
Stifel lowered the firm’s price target on Staar Surgical (STAA) to $28 from $31 and keeps a Hold rating on the shares. The Q2 update was net positive, with China…
Staar Surgical price target lowered to $19 from $20 at UBS
UBS lowered the firm’s price target on Staar Surgical (STAA) to $19 from $20 and keeps a Sell rating on the shares.
STAAR Surgical Company Earnings Call Transcript: Q2 2026
Record revenue and profitability were achieved, led by strong EVO+ adoption in China and growth in the U.S. Gross margin improved, cash increased, and the company remains debt-free. Outlook calls for continued growth, with supply constraints easing and innovation initiatives advancing.
STAAR Surgical Company Earnings release: Q2 2026
STAAR Surgical Company released its Q2 2026 earnings on August 12, 2026, summarizing the period's financial results.
STAAR Surgical Company Quarterly report: Q2 2026
STAAR Surgical Company has published its Q2 2026 quarterly earnings report on August 12, 2026.
STAAR Surgical Reports Second Quarter 2026 Results
LAKE FOREST, Calif.--(BUSINESS WIRE)--STAAR Surgical Company (NASDAQ: STAA), the global leader in phakic IOLs with the EVO™ family of Implantable Collamer® Lenses (EVO ICL™) for vision correction, tod...
Staar Surgical appoints Warren Foust as president, CEO
STAAR Surgical (STAA) Company announced that following an extensive global search, its Board of Directors has appointed Warren Foust as President and CEO and a new member of the Board…
STAAR Surgical Appoints Warren Foust as President and Chief Executive Officer
LAKE FOREST, Calif.--(BUSINESS WIRE)--STAAR Surgical Company ("STAAR" or the "Company") (NASDAQ: STAA), the global leader in phakic IOLs with the EVO family of Implantable Collamer® Lenses (EVO ICL™) ...
STAAR Surgical to Host Second Quarter 2026 Earnings Results Call and Webcast on August 12, 2026
LAKE FOREST, Calif.--(BUSINESS WIRE)--STAAR Surgical Company (NASDAQ: STAA), the global leader in phakic IOLs with the EVO family of Implantable Collamer® Lenses (EVO ICL™) for vision correction, toda...
Staar Surgical initiated with a Sell at UBS
UBS analyst Patrick Wood initiated coverage of Staar Surgical (STAA) with a Sell rating and $20 price target The eyecare sector is healthier than expected, with resilient U.S. consumer demand,…
Staar Surgical initiated with a Sell at UBS
UBS initiated coverage of Staar Surgical (STAA) with a Sell rating and $20 price target
Staar Surgical sees Q2 revenue above $90M, consensus $90.2M
Staar Surgical (STAA) states: “The Company delivered strong second quarter net sales, led by sequential growth in China, solid growth across the broader Asia-Pacific region, and double-digit percentag...
STAAR Surgical Announces Preliminary Net Sales for Second Quarter 2026
LAKE FOREST, Calif.--(BUSINESS WIRE)--STAAR Surgical Company (NASDAQ: STAA), the global leader in phakic IOLs with the EVO™ family of Implantable Collamer® Lenses (EVO ICL™) for vision correction, tod...
STAAR Surgical Company Transcript: AGM 2026
The meeting covered board elections, equity plan amendments, auditor ratification, and executive compensation, with all proposals receiving majority approval. Governance matters were the primary focus, and final voting results will be filed with the SEC.
STAAR Surgical Company Transcript: Status update
Q1 saw strong revenue growth in China and the U.S., driven by EVO+ demand and targeted marketing. Guidance remains cautious due to market unpredictability, but gross margin and operating expense targets are set, with ongoing investments in innovation and infrastructure.
STAAR Surgical Company Transcript: Stifel 2026 Virtual Ophthalmology Forum
China's refractive market stabilized in 2025, with Q1 2026 showing strong demand and evolving seasonality due to military conscription. Ex-China markets grew broadly, while innovation focuses on EVO+ and ERP upgrades. Margin expansion is expected from manufacturing and process efficiencies.
STAAR Surgical Announces Participation in Upcoming Investor Conferences
LAKE FOREST, Calif.--(BUSINESS WIRE)--STAAR Surgical Company (NASDAQ: STAA), the global leader in phakic IOLs with the EVO family of Implantable Collamer® Lenses (EVO ICL™) for vision correction, toda...
Staar Surgical upgraded to Outperform from Neutral at Wedbush
Wedbush upgraded Staar Surgical (STAA) to Outperform from Neutral with a price target of $40, up from $26.
Staar Surgical price target raised to $32 from $27 at Canaccord
Canaccord raised the firm’s price target on Staar Surgical (STAA) to $32 from $27 and keeps a Buy rating on the shares. The firm updated its model following clean Q1…
Staar Surgical price target raised to $27 from $22 at Mizuho
Mizuho analyst Anthony Petrone raised the firm’s price target on Staar Surgical (STAA) to $27 from $22 and keeps a Neutral rating on the shares. The company’s Q1 results were…
Wedbush upgrades Staar Surgical to Outperform on China rebound
Wedbush upgraded Staar Surgical (STAA) to Outperform from Neutral with a price target of $40, up from $26. The Q1 report brings confidence that Staar is either at or nearing…
Staar Surgical price target raised to $31 from $18 at Stifel
Stifel analyst Thomas Stephan raised the firm’s price target on Staar Surgical (STAA) to $31 from $18 and keeps a Hold rating on the shares.
Staar Surgical price target raised to $33 from $16 at Piper Sandler
Piper Sandler analyst Adam Maeder raised the firm’s price target on Staar Surgical (STAA) to $33 from $16 and keeps a Neutral rating on the shares. The firm notes the…
STAAR Surgical Company Earnings Call Transcript: Q1 2026
Q1 2026 saw robust sales growth, a return to profitability, and improved margins, led by strong China performance and disciplined cost control. Management remains optimistic but cautious on guidance due to ongoing macro and geopolitical risks.
STAAR Surgical Company Earnings release: Q1 2026
STAAR Surgical Company released its Q1 2026 earnings on May 13, 2026, summarizing the period's financial results.